Provided by Tiger Trade Technology Pte. Ltd.

Coherus BioSciences

1.41
-0.0200-1.40%
Post-market: 1.40-0.0100-0.71%19:34 EDT
Volume:446.40K
Turnover:631.27K
Market Cap:217.45M
PE:0.93
High:1.45
Open:1.44
Low:1.40
Close:1.43
52wk High:2.62
52wk Low:0.8100
Shares:154.22M
Float Shares:135.00M
Volume Ratio:1.06
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.52
EPS(LYR):1.43
ROE:331.11%
ROA:-32.80%
PB:2.77
PE(LYR):0.98

Loading ...

Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study

TIPRANKS
·
Jun 24

Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics

MT Newswires Live
·
Jun 24

BRIEF-Coherus, Zumutor To Collaborate On ZM008, LOQTORZI Combination Study

Reuters
·
Jun 24

Coherus Oncology, Zumutor Biologics team up on Phase 1 trial combining ZM008 with LOQTORZI

Reuters
·
Jun 24

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate Zm008 in Combination With Loqtorzi® (Toripalimab-Tpzi)

THOMSON REUTERS
·
Jun 24

Coherus Oncology: Co to Supply Loqtorzi; Zumutor to Sponsor Phase 1 Trial; Both Retain Commercial Rights

THOMSON REUTERS
·
Jun 24

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Coherus Biosciences (CHRS)

TIPRANKS
·
Jun 22

Coherus Oncology dismisses EY, names PwC as new auditor

Reuters
·
Jun 16

Sona Nanotech appoints ex-Coherus executive Michael Fleming to board

Reuters
·
Jun 11

Coherus Oncology shareholders approve stock option repricing plan at annual meeting

Reuters
·
Jun 01

Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Medicinova (MNOV)

TIPRANKS
·
May 29

Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives

Simply Wall St.
·
May 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

TIPRANKS
·
May 12

Coherus Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Coherus Oncology Q1 Sales USD 12.31 Million Vs. IBES Estimate USD 14.3 Million

Reuters
·
May 12

Coherus Oncology Q1 sales rise

Reuters
·
May 12

Coherus BioSciences Q1 Adj. EPS $(0.25) Beats $(0.27) Estimate, Sales $12.310M Miss $14.342M Estimate

Benzinga
·
May 12

Coherus Q1 FY26 operating loss narrows to $36.15 million; revenue rises to $12.31 million

Reuters
·
May 12

Coherus Oncology Q1 Sales USD 12.31 Million VS. Ibes Estimate USD 14.3 Million

THOMSON REUTERS
·
May 12

Coherus Oncology Q1 EPS USD -0.28

THOMSON REUTERS
·
May 12